XSDR:LSE:LSE-Xtrackers MSCI Europe Health Care ESG Screened UCITS ETF 1C (GBX)

ETF | Others |

Last Closing

USD 19734

Change

-197.00 (-0.99)%

Market Cap

USD 0.21B

Volume

27.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-4.75 (-2.49%)

USD 1,607.29B
0R1O:LSE Amazon.com Inc.

-4.75 (-2.49%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-0.84 (-0.70%)

USD 618.20B
0R1I:LSE NVIDIA Corp.

-0.84 (-0.70%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.05 (-0.38%)

USD 572.76B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.05 (-0.38%)

USD 572.76B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.08 (-0.45%)

USD 572.76B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.08 (-0.45%)

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B

ETFs Containing XSDR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.68% 62% D 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.68% 61% D- 62% D
Trailing 12 Months  
Capital Gain 12.16% 43% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.16% 41% F 48% F
Trailing 5 Years  
Capital Gain 54.66% 68% D+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.66% 66% D+ 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 8.26% N/A N/A 65% D
Dividend Return 8.26% N/A N/A 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.37% N/A N/A 90% A-
Risk Adjusted Return 129.62% N/A N/A 99% N/A
Market Capitalization 0.21B 61% D- 35% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike